SeQuent announced launch of Citramox® LA in EU

SeQuent Scientific Limited (SeQuent), announced launch of Citramox® LA 150 mg/ml Suspension Injection for Cattle and Pigs in 10 European countries, including the key markets of Western Europe. The product has recently received approval through its Spanish subsidiary Laboratorios Karizoo, S.A., and will be the first Long-Acting injectable to be offered by SeQuent in Europe.

This new approval for SeQuent builds on the recent approvals of Tulazzin® (Tulathromycin) and Halofusol® (Halofuginone) in Europe. All these approvals have been received within 12 months of filing, which reflects on SeQuent's growing strengths in introducing new products for the regulated markets.

Citramox® is the first generic version of Vetrimoxin LA (Innovator: Ceva Animal Health Inc) to be approved and launched in Europe, which is an effective antibiotic indicated for the treatment of respiratory infections caused by Mannheimia haemolytica and Pasteurella multocida susceptible to amoxicillin in cattle and pigs. Citramox® formulation has good homogeneity and high fluidity profile, which along with its user-friendly plastic vial packaging and withdrawal times offers superior value to farmers.

The market size in Europe for Amoxicillin Long-Acting products is estimated to be ~Euro 20 Million.

Shares of SEQUENT SCIENTIFIC LTD. was last trading in BSE at Rs.169.9 as compared to the previous close of Rs. 173.95. The total number of shares traded during the day was 42068 in over 819 trades.

The stock hit an intraday high of Rs. 175 and intraday low of 169.1. The net turnover during the day was Rs. 7203625.

Source : Equity Bulls

Keywords